Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, postponed its IPO on Tuesday, citing poor market conditions. The Rutherford, NJ-based company was founded in 1999 and booked $4 million in sales for the year ended 12/31/2012. Aegis Capital was set to be the sole bookrunner on the deal.
This was the diagnostics company's third postponement. Cancer Genetics previously attempted to price in May 2012 ($48 million deal size) and February 2013 ($35 million deal size).
